We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The mounting controversy over Cox-2 inhibitors is having a positive effect on
Abbott Laboratories' bottom line, which was bolstered during the fourth quarter
by strong sales of Mobic, a pain reliever that Abbott co-markets with Boehringer
Ingelheim Pharmaceuticals.
Maryland has laid plans to join a multistate prescription
drug buying agreement that would let the states combine their Medicaid purchasing
power to seek deeper discounts from drugmakers.
Mounting concerns over the safety of Cox-2 inhibitors is having a negative impact
on medical research, including large studies on the prevention and treatment
of cancer, rheumatoid arthritis and osteoarthritis, dementia, and other diseases,
industry experts warn.
PhytoMedical Technologies, an early-stage research-based biopharmaceutical company
specializing in the discovery, development and eventual commercialization of
innovative plant-derived pharmaceutical and nutraceutical compounds, has announced
that Connecticut-based, Planta Analytica, will undertake the extraction, fractionation
and isolation of potentially active pharmacological elements in PhytoMedical's
BDC-03, a plant-derived compound that has been successful in reducing body fat
percentage, increasing lean muscle mass and lowering cholesterol in studies
of growing animals.
A Miami man has pleaded guilty in federal court to his role in a multimillion
dollar conspiracy to sell counterfeit and illegally imported Lipitor in the
U.S. Julio Cesar Cruz, 42, pleaded guilty Friday in U.S. District Court in Kansas
City to charges that he sold the counterfeit drugs and conspired to sell them
between February 2002 and April 2003.
BioAdvance is set to unveil its third round of investments, which will provide
roughly $3.5 million to seven local life sciences researchers or companies.
CoTherix, strengthened by regulatory approval of its drug for pulmonary hypertension,
filed a registration statement with the SEC for a 4 million-share offering.
Li-Taka Pharmaceuticals, a Pune-based Pharmaceutical Formulation Company, has
recently entered into a manufacturing agreement with Wockhardt for manufacturing
of Anti-TB range of products.
Peregrine Pharmaceuticals, a biopharmaceutical company with a broad portfolio
of products under development, has entered into an agreement with Merck KGaA
of Darmstadt, Germany, that will give Peregrine access to Merck's technology
and expertise in protein expression.
Dharmacon, the world's leading supplier of innovative
RNA and RNA interference (RNAi) research products, has announced that Genentech
has selected Dharmacon's advanced RNAi technology for use in its drug discovery
and development research.